

**A Comprehensive Board Review in Hematology and Medical Oncology**

**9/15/2025 7:00:00 AM - 9/20/2025 5:30:00 PM**

**Target Audience:**

Professions: Physician (MD or DO), Nurse - RN, Pharmacist, Pharmacy Technician, Student or Trainee, Nurse - LVN, Nurse - APRN

**Description:**

The course is a 6-day comprehensive review of current standards and practices in the management of patients with blood disorders and malignancy. The course is designed to enable the participant to effectively prepare for the American Board of Internal Medicine certification and recertification examinations in Hematology and Medical Oncology. Advances in clinical pharmacology, molecular genetics and risk assessment, and radiation oncology will be included.

**Learning Objectives:**

1 Apply knowledge gained to prepare for the hematology and medical oncology subspecialty and recertification examinations in hematology and medical oncology.

2 Utilize current standards of care for patients with cancer, blood disorders and malignancies.

3 Demonstrate proficiency of knowledge in hematology and medical oncology.

4 Incorporate recent advances in management of hematologic and oncologic patients.

|  |  |
| --- | --- |
|  |  |

**Accreditation:**

|  |  |
| --- | --- |
|  | In support of improving patient care, The University of Texas MD Anderson Cancer Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |

**Credit Designation**:

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 51.00 *AMA PRA Category 1* *Credits*TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



**American Board of Internal Medicine MOC Credit:**

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 51.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

**Disclosure of Financial Relationships:**

The University of Texas MD Anderson Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

**Faculty & Planner Disclosure:**

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| Felisha Estelle, BBA | Other Planning Committee Member | Nothing to disclose - 07/08/2025 |
| Rodabe N. Amaria, MD | Faculty | Grant or research support-Novartis Pharmaceuticals Corporation (Relationship has ended)|Grant or research support-KSQ|Grant or research support-Erasca|Grant or research support-Erasca|Consulting Fee-Obsidian |Grant or research support-Merck Sharp & Dohme Corp. (any division) (Relationship has ended)|Grant or research support-Bristol-Myers Squibb Company (Relationship has ended)|Grant or research support-Regeneron Pharmaceuticals, Inc.|Grant or research support-Iovance (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Novartis Pharmaceuticals Corporation (Relationship has ended)|Grant or research support-Obsidian|Grant or research support-OnKure|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Bristol-Myers Squibb Company (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-TIL Working Group|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Nektar (Relationship has ended) - 01/24/2025 |
| Nishin Bhadkamkar, MD | Other Planning Committee Member | Nothing to disclose - 03/03/2025 |
| Senthilkumar Damodaran, MD | Faculty | Nothing to disclose - 02/12/2025 |
| Courtney D. DiNardo, MD | Faculty | Honoraria-AbbVie Inc.|Honoraria-Rigel|Honoraria-Daiichi Sankyo, Inc.|Honoraria-Gilead Sciences, Inc. (Relationship has ended)|Honoraria-Genentech, Inc.|Honoraria-Astellas Scientific and Medical Affairs, Inc. (Relationship has ended)|Honoraria-Bristol-Myers Squibb Company|Honoraria-GlaxoSmithKline|Honoraria-Jazz Pharmaceuticals|Honoraria-Novartis Pharmaceuticals Corporation (Relationship has ended)|Honoraria-Servier Pharmaceuticals|Honoraria-Immunogen (Relationship has ended)|Consulting Fee-Schrodinger|Advisor-Ellipses - 08/08/2025 |
| Yvonne J. Heung, MD | Faculty | Nothing to disclose - 05/08/2025 |
| Eric Jonasch, MD | Faculty | Consulting Fee-Aveo|Grant or research support-ProFoundBio|Grant or research support-AbbVie Inc.|Grant or research support-Telix|Grant or research support-Aveo|Grant or research support-Corvus|Consulting Fee-Aravive (Relationship has ended)|Grant or research support-Arrowhead|Consulting Fee-Eisai, Inc.|Honoraria-Exelixis|Honoraria-Ipsen US|Honoraria-Merck Research Laboratories and the Office of the Chief Medical Officer Grants|Grant or research support-Merck Research Laboratories and the Office of the Chief Medical Officer Grants|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Novartis Pharmaceuticals Corporation|Honoraria-Nikang|Grant or research support-Nikang|Honoraria-Takeda (Relationship has ended)|Honoraria-DAVA - 09/27/2024 |
| Tapan M. Kadia, MD | Co-Director, Faculty | Grant or research support-Bristol-Myers Squibb Company|Honoraria-DAVA Oncology|Speakers Bureau-CURE|Honoraria-DrenBio|Grant or research support-Dren Bio|Grant or research support-Celgene Corporation (Relationship has ended)|Grant or research support-BMS|Honoraria-Biologix (Relationship has ended)|Grant or research support-Janssen Biotech, Inc. (Relationship has ended)|Grant or research support-Incyte Corporation|Grant or research support-Astex|Grant or research support-Abcuro|Grant or research support-Pfizer Inc.|Honoraria-Hikma Pharmaceuticals|Consulting Fee-Genzyme Corporation (Relationship has ended)|Grant or research support-Glycomimetics|Consulting Fee-Sellas|Grant or research support-Sellas|Grant or research support-AbbVie Inc.|Grant or research support-Amgen Inc. (Relationship has ended)|Grant or research support-Genentech, Inc.|Grant or research support-Ascentage|Grant or research support-Cellenkos (Relationship has ended)|Grant or research support-AstraZeneca US (Relationship has ended)|Grant or research support-Astellas Scientific and Medical Affairs, Inc. (Relationship has ended)|Paid consultant-AbbVie Inc.|Paid consultant-Genentech, Inc.|Grant or research support-Genfleet|Grant or research support-Sellas, Inc|Grant or research support-Delta Fly Pharma (Relationship has ended)|Grant or research support-Jazz Pharmaceuticals|Paid consultant-Jazz Pharmaceuticals|Paid consultant-Novartis Pharmaceuticals Corporation|Paid consultant-Daiichi Sankyo, Inc.|Paid consultant-Agios Pharmaceuticals Inc.|Consulting Fee-PinotBio (Relationship has ended)|Consulting Fee-Sanofi US (Relationship has ended)|Paid consultant-Pfizer Inc.|Grant or research support-Regeneron Pharmaceuticals, Inc.|Consulting Fee-Servier Pharmaceuticals|Consulting Fee-Syndax|Consulting Fee-Kura - 03/03/2025 |
| Hagop M. Kantarjian, MD | Faculty | Grant or research support-AbbVie Inc.|Grant or research support-Amgen Inc.|Grant or research support-Pfizer Inc.|Grant or research support-Takeda|Consulting Fee-AbbVie Inc.|Consulting Fee-Amgen Inc.|Consulting Fee-Bristol-Myers Squibb Company|Consulting Fee-Pfizer Inc.|Consulting Fee-Takeda - 08/11/2025 |
| Meghan S. Karuturi, MD | Faculty | Nothing to disclose - 09/05/2025 |
| Edmund S. Kopetz, MD | Faculty | Advisor-Lutris Pharmaceuticals (Relationship has ended)|Consulting Fee-Genentech, Inc.|Grant or research support-EMD Serono Inc.|Consulting Fee-Merck Research Laboratories and the Office of the Chief Medical Officer Grants|Grant or research support-Novartis Pharmaceuticals Corporation (Relationship has ended)|Grant or research support-Lilly USA, LLC|Consulting Fee-Boehringer Ingelheim|Grant or research support-Boehringer Ingelheim|Consulting Fee-Bayer HealthCare Pharmaceuticals, Inc.|Grant or research support-Daiichi Sankyo, Inc.|Consulting Fee-Pfizer Inc.|Grant or research support-Jazz Pharmaceuticals|Consulting Fee-Mirati Therapeutics|Consulting Fee-Flame Biosciences|Consulting Fee-Carina Biotechnology|Grant or research support-Sanofi US (Relationship has ended)|Grant or research support-Guardant Health|Grant or research support-Genentech, Inc.|Grant or research support-MedImmune (Relationship has ended)|Grant or research support-Amgen Inc.|Grant or research support-Lilly USA, LLC|Advisor-Frontier Medicines|Consulting Fee-Frontier Medicines|Consulting Fee-Replimune|Consulting Fee-Bristol-Myers Squibb-Medarex|Consulting Fee-Amgen|Consulting Fee-Tempus|Consulting Fee-Harbinger Oncology|Consulting Fee-Zentalis|Consulting Fee-AVEO|Consulting Fee-Tachyon Therapeutics|Consulting Fee-Agenus|Consulting Fee-Revolution Medicines|Consulting Fee-Kestrel Therapeutics|Consulting Fee-Roche|Grant or research support-BridgeBio|Grant or research support-Cardiff|Grant or research support-Zentalis|Grant or research support-Mirati (Relationship has ended)|Consulting Fee-Arcus Biosciences|Consulting Fee-AstraZeneca Pharmaceutical|Consulting Fee-BeiGene|Consulting Fee-Clasp Therapeutics|Consulting Fee-Cytovation|Consulting Fee-Dewpoint Therapeutics|Consulting Fee-Marengo Therapeutics|Consulting Fee- SageMedic|Consulting Fee-Servier|Consulting Fee-Sibylla|Consulting Fee-T-Cypher Bio|Consulting Fee-XAIRA|Consulting Fee-AmMax Bio|Consulting Fee-Ikena|Grant or research support-Sankyo|Grant or research support-Pfizer Inc.|Grant or research support-BioMed Valley - 08/15/2025 |
| Leonard J Medeiros, MD | Faculty | Nothing to disclose - 02/21/2025 |
| Shreyaskumar Patel, MD | Faculty, Other Planning Committee Member | Consulting Fee-Daiichi Sankyo, Inc.|Consulting Fee-Deciphera|Consulting Fee-Kura Oncology - 01/21/2025 |
| Samuel A. Shelburne III, MD, Fellow Infectious Diseases Society of America | Faculty | Nothing to disclose - 07/08/2025 |
| Jason R. Westin, MD | Faculty | Grant or research support-AstraZeneca US|Grant or research support-Allogene|Paid consultant-Allogene|Paid consultant-AbbVie Inc.|Paid consultant-Nurix|Grant or research support-Nurix|Paid consultant-Pfizer Inc.|Grant or research support-Merck Sharp & Dohme Corp. (any division) (Relationship has ended)|Paid consultant-ADC Therapeutics|Paid consultant-Morphosys|Paid consultant-Novartis Pharmaceuticals Corporation|Paid consultant-Gilead Sciences, Inc.|Paid consultant-Genentech, Inc.|Grant or research support-Johnson & Johnson (any division)|Grant or research support-Gilead Sciences, Inc.|Grant or research support-Bristol-Myers Squibb Company|Grant or research support-Morphosys|Grant or research support-Genentech, Inc. - 08/08/2025 |
| Robert A. Wolff, MD | Faculty | Nothing to disclose - 09/23/2024 |
| Jose A. Rauh-Hain, MD | Faculty | Nothing to disclose - 11/25/2024 |
| Paolo Strati, MD | Faculty | Consulting Fee-Genentech, Inc.|Advisor-Incyte (Relationship has ended)|Advisor-Sobi (Relationship has ended)|Advisor-ADC Therapeutics (Relationship has ended)|Grant or research support-ADC Therapeutics|Advisor-TG Therapeutics (Relationship has ended)|Advisor-Hutchinson MediPharma (Relationship has ended)|Advisor-Kite-Gilead (Relationship has ended)|Grant or research support-Gilead Sciences, Inc.|Advisor-AstraZeneca US (Relationship has ended)|Grant or research support-AstraZeneca US|Grant or research support-ALX Oncology|Advisor-AbbVie Inc.|Advisor-Genmab|Advisor-Ipsen US|Advisor-Novartis Pharmaceuticals Corporation - 08/12/2025 |
| Mimi I. Hu, MD | Faculty | Grant or research support-Lilly USA, LLC|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Lilly USA, LLC - 07/01/2025 |
| Arlene O. Siefker-Radtke, MD | Faculty | Membership on Advisory Committees or Review Panels, Board Membership, etc.-Janssen Biotech, Inc.|Honoraria-Immunomedics|Honoraria-Loxo|Honoraria-Janssen Biotech, Inc.|Honoraria-Merck Sharp & Dohme Corp. (any division)|Honoraria-Gilead Sciences, Inc.|Grant or research support-Bristol-Myers Squibb Company|Grant or research support-Janssen Biotech, Inc.|Grant or research support-Merck Research Laboratories and the Office of the Chief Medical Officer Grants|Honoraria-Bristol-Myers Squibb Company|Honoraria-Seattle Genetics, Inc.|Honoraria-Taiho Oncology, Inc.|Grant or research support-Basilea Pharmaceutica|Honoraria-G1 Therapeutics|Honoraria-AbbVie Inc.|Honoraria-Astellas Scientific and Medical Affairs, Inc. - 08/08/2025 |
| Jennifer K. Litton, MD | Faculty | Grant or research support-Pfizer Inc. (Relationship has ended)|Grant or research support-Merck Research Laboratories and the Office of the Chief Medical Officer Grants (Relationship has ended)|Grant or research support-Zenith (Relationship has ended)|Grant or research support-AstraZeneca US (Relationship has ended)|Grant or research support-EMD Serono Inc. (Relationship has ended)|Grant or research support-GlaxoSmithKline (Relationship has ended)|Grant or research support-Genentech, Inc. (Relationship has ended)|Speakers Bureau-Clinical Care Options|Royalties or Patent Beneficiary-Certis|Speakers Bureau-tumorboardtues (Relationship has ended) - 01/21/2025 |
| Alessandra Ferrajoli, MD | Other Planning Committee Member | Membership on Advisory Committees or Review Panels, Board Membership, etc.-AbbVie Inc. (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-AstraZeneca US (Relationship has ended) - 02/25/2025 |
| Caitlin R Rausch, PharmD, BCOP | Faculty | Nothing to disclose - 07/01/2025 |
| Kelly S. Chien, MD | Faculty | Nothing to disclose - 02/04/2025 |
| Sharon H. Giordano, MD, FASCO | CE Reviewer, Co-Director, Faculty | Nothing to disclose - 02/24/2025 |
| Carl M. Gay, MD | Faculty | Advisor-G1 Therapeutics (Relationship has ended)|Advisor-Boehringer Ingelheim (Relationship has ended)|Advisor-Amgen Inc. (Relationship has ended)|Advisor-BeOne (Relationship has ended)|Advisor-Abdera Therapeutics (Relationship has ended)|Advisor-AstraZeneca US (Relationship has ended)|Advisor-Jazz Pharmaceuticals|Grant or research support-AstraZeneca US|Speakers Bureau-AstraZeneca US|Advisor-Daiichi Sankyo, Inc. (Relationship has ended)|Advisor-Catalyst (Relationship has ended)|Speakers Bureau-Dava Oncology (Relationship has ended) - 07/02/2025 |
| Neal S. Akhave, MD | Faculty | Consulting Fee-Pfizer Inc. (Relationship has ended) - 07/25/2025 |
| Mariana C. Chavez MacGregor, MD, Profesor | Faculty | Grant or research support-Novartis Pharmaceuticals Corporation (Relationship has ended)|Advisor-Novartis Pharmaceuticals Corporation|Consulting Fee-Merck Research Laboratories and the Office of the Chief Medical Officer Grants (Relationship has ended)|Grant or research support-Lilly USA, LLC|Consulting Fee-Daiichi Sankyo, Inc. (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Pfizer Inc.|Membership on Advisory Committees or Review Panels, Board Membership, etc.-AstraZeneca US|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Genentech, Inc.|Advisor-Genomic Health, Inc. (Relationship has ended) - 07/31/2025 |
| Kaiwen Wang, PharmD | Faculty | Advisor-Pfizer Inc.|Advisor-Janssen Biotech, Inc. - 07/25/2025 |
| Abenaa M. Brewster, MD | Faculty | Nothing to disclose - 07/04/2025 |
| Martha Mims, MD, PhD | Co-Director, Faculty | Stocks or stock options, excluding diversified mutual funds-Amgen Inc.|Stocks or stock options, excluding diversified mutual funds-Biogen Inc.|Grant or research support-Janssen Biotech, Inc.|Grant or research support-Celgene Corporation|Grant or research support-Incyte Corporation|Grant or research support-inovio - 03/05/2025 |
| Kenneth Bauer, MD, Physician | Faculty | Consulting Fee-Sanofi US (Relationship has ended) - 07/03/2025 |
| Jorge Cortes, MD | Faculty | Advisor-Pfizer Inc.|Advisor-Novartis Pharmaceuticals Corporation|Grant or research support-Novartis Pharmaceuticals Corporation|Advisor-Sun Pharma|Grant or research support-Sun Pharma|Advisor-Takeda|Advisor-BioPath Holdings|Grant or research support-AbbVie Inc.|Grant or research support-Ascentage|Advisor-Ascentage|Advisor-Tern Pharma|Advisor-Syndax|Grant or research support-Kuro Oncology - 06/24/2025 |
| Ravin J. Garg, MD | Faculty | Nothing to disclose - 07/03/2025 |
| Nasser H. Hanna, MD | Faculty | Grant or research support-Merck Research Laboratories and the Office of the Chief Medical Officer Grants|Grant or research support-Genentech, Inc. - 06/24/2025 |
| Claudine Isaacs, MD, FRCPC | Faculty | Consulting Fee-Genentech, Inc.|Consulting Fee-Seattle Genetics, Inc.|Consulting Fee-AstraZeneca US|Consulting Fee-Novartis Pharmaceuticals Corporation|Consulting Fee-PUMA|Consulting Fee-Pfizer Inc.|Consulting Fee-ION Solutions (Relationship has ended)|Consulting Fee-Gilead Sciences, Inc.|Consulting Fee-Merck Sharp & Dohme Corp. (any division)|Honoraria-Medscape|Honoraria-MJH Holdings|Royalties or Patent Beneficiary-Wolters Kluwer|Royalties or Patent Beneficiary-McGraw Hill - 07/25/2025 |
| Mark Lewis, MD | Faculty | Nothing to disclose - 08/08/2025 |
| Alice Ma, MD | Faculty | Consulting Fee-Pfizer Inc. (Relationship has ended) - 07/01/2025 |
| Stephan Moll, MD | Faculty | Nothing to disclose - 07/09/2025 |
| Susan O'Brien, MD | Faculty | Consulting Fee-AbbVie Inc.|Consulting Fee-Regeneron Pharmaceuticals, Inc.|Consulting Fee-Pharmacyclics LLC|Consulting Fee-Johnson & Johnson (any division)|Consulting Fee-Janssen Biotech, Inc.|Consulting Fee-GlaxoSmithKline|Consulting Fee-Genentech, Inc.|Consulting Fee-Bristol-Myers Squibb Company|Consulting Fee-AstraZeneca US|Grant or research support-Caribou|Consulting Fee-Autolus - 07/10/2025 |
| Timothy Olson, MD, PhD | Faculty | Consulting Fee-bluebird bio|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Miltenyi (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Pfizer Inc. (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Medexus (Relationship has ended)|Other: Data Safey Monitoring Board-Elixergin Therapeutics (Relationship has ended) - 06/24/2025 |
| Antonio Omuro, MD | Faculty | Grant or research support-Arcus Biosciences|Consulting Fee-Ono Pharma USA, Inc (Relationship has ended)|Consulting Fee-Servier Pharmaceuticals (Relationship has ended)|Consulting Fee-Curevac AG (Relationship has ended)|Consulting Fee-Nurix (Relationship has ended)|Consulting Fee-Telix (Relationship has ended) - 07/01/2025 |
| S. Vincent Rajkumar, MD | Faculty | Nothing to disclose - 07/01/2025 |
| A. Koneti Rao, MD | Faculty | Nothing to disclose - 08/01/2025 |
| William N. William Jr., MD | Faculty | Consulting Fee-AstraZeneca US|Consulting Fee-Amgen Inc.|Consulting Fee-Bayer HealthCare Pharmaceuticals, Inc.|Consulting Fee-Boehringer Ingelheim|Consulting Fee-Bristol-Myers Squibb Company|Consulting Fee-Janssen Biotech, Inc.|Consulting Fee-Lilly USA, LLC|Consulting Fee-Merck Sharp & Dohme Corp. (any division)|Consulting Fee-Novartis Pharmaceuticals Corporation|Consulting Fee-Pfizer Inc.|Consulting Fee-Sanofi Genzyme|Consulting Fee-Genentech, Inc. - 06/24/2025 |
| Harry H. Yoon, MD | Faculty | Grant or research support-Bristol-Myers Squibb Company|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Daiichi Sankyo, Inc.|Advisor-Janssen Biotech, Inc. (Relationship has ended)|Advisor-Bayer HealthCare Pharmaceuticals, Inc. (Relationship has ended)|Grant or research support-BeiGene|Grant or research support-Amgen Inc.|Grant or research support-CARsgen Therapeutics|Grant or research support-Macrogenics|Grant or research support-Merck Sharp & Dohme Corp. (any division)|Advisor-ALX Oncology|Advisor-AstraZeneca US|Advisor-BeiGene|Advisor-Bristol-Myers Squibb Company|Advisor-Macrogenics|Advisor-Merck Sharp & Dohme Corp. (any division)|Advisor-OncXerna|Advisor-Zymeworks|Advisor-Novartis Pharmaceuticals Corporation|Advisor-Astellas Scientific and Medical Affairs, Inc.|Advisor-Elevation Oncology (Relationship has ended)|Advisor-Amgen Inc. - 07/08/2025 |
| Timothy D. Gilligan, MD, FASCO, FACH | Faculty | Nothing to disclose - 02/19/2025 |
| Betty Hamilton, MD | Faculty | Membership on Advisory Committees or Review Panels, Board Membership, etc.-Incyte Corporation|Grant or research support-Angiocrine|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Maat Pharma (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Sanofi US|Membership on Advisory Committees or Review Panels, Board Membership, etc.-CSL Behring|Honoraria-ACI Group - 08/08/2025 |
| Nancy Berliner, MD | Faculty | Nothing to disclose - 06/24/2025 |
| Claire Mach, PharmD | Faculty | Nothing to disclose - 07/15/2025 |
| Kerry O'Brien, MD | Faculty | Nothing to disclose - 07/01/2025 |
| Raajit Rampal, MD, PhD | Faculty | Consulting Fee-Incyte Corporation|Consulting Fee-Celgene Corporation|Consulting Fee-Bristol-Myers Squibb Company|Consulting Fee-Blueprint Medicines Corporation|Consulting Fee-AbbVie Inc.|Consulting Fee-CTI|Consulting Fee-Stemline|Consulting Fee-Galecto|Consulting Fee-Pharmaessentia|Consulting Fee-Jubilant|Consulting Fee-Constellation|Consulting Fee-Morphosys|Consulting Fee-Sierra Oncology|Consulting Fee-GSK|Consulting Fee-Protagonist|Consulting Fee-Cogent|Consulting Fee-Sumitomo Dainippon|Consulting Fee-Kartos|Consulting Fee-Servier Pharmaceuticals|Consulting Fee-Zentalis|Consulting Fee-Karyopharm Therapeutics|Grant or research support-Constellation Pharmaceuticals|Grant or research support-Ryvu|Grant or research support-Zentalis|Grant or research support-Stemline Therapeutics|Grant or research support-Incyte Corporation - 08/14/2025 |
| Bradley Carthon, MD, PhD, MD, PhD | Faculty | Nothing to disclose - 07/16/2025 |
| Senthil Sukumar, MD | Faculty | Honoraria-Sanofi Genzyme (Relationship has ended)|Honoraria-Alexion Pharmaceuticals, Inc. (Relationship has ended) - 07/17/2025 |
| Gerald A Soff, MD | Faculty | Grant or research support-Amgen Inc.|Grant or research support-Janssen Biotech, Inc. (Relationship has ended)|Grant or research support-Sobi Pharmaceuticals|Grant or research support-Anthos Therapeutics (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Alpine Immune Sciences, a Vertex Company|Consulting Fee-Sanofi Genzyme|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Novartis Pharmaceuticals Corporation - 07/22/2025 |
| Alison Moskowitz, MD | Faculty | Other: speaking-Takeda Pharmaceuticals (Relationship has ended)|Advisor-Pfizer Inc.|Other: speaking-Medscape (Relationship has ended)|Other: speaking-Tessa Therapeutics (Relationship has ended)|Other: speaking-Seagen (Relationship has ended)|Other: advisory-Affimed (Relationship has ended)|Other: advisory-Janpix Limited (Relationship has ended)|Other: advisory-Seattle Genetics (Relationship has ended)|Other: advisory-Kyowa Hakko Kirin Pharma (Relationship has ended)|Grant or research support-Incyte Corporation|Grant or research support-Merck Sharp & Dohme Corp. (any division)|Grant or research support-Bristol-Myers Squibb Company|Grant or research support-Secura-Bio - 07/09/2025 |
| Bethany T Samuelson Bannow, MD, MCR | Faculty | Consulting Fee-Hemabiologics (Relationship has ended) - 07/07/2025 |
| Carla Casulo, MD | Faculty | Honoraria- Mashup Media (Relationship has ended)|Consulting Fee- Mashup Media (Relationship has ended)|Consulting Fee-Bristol-Myers Squibb Company|Honoraria-Bristol-Myers Squibb Company|Consulting Fee-AbbVie Inc.|Honoraria-AbbVie Inc.|Consulting Fee-Genentech, Inc.|Honoraria-Genentech, Inc.|Grant or research support-Genmab|Grant or research support-Gilead Sciences, Inc.|Grant or research support-Genentech, Inc.|Membership on Advisory Committees or Review Panels, Board Membership, etc.-FL Cures Foundation (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-American Society of Hematology|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Lymphoma Research Foundation|Honoraria-Genmab|Consulting Fee-Genmab - 07/28/2025 |
| Emily Hinchcliff, MD | Faculty | Speakers Bureau-AbbVie Inc. - 07/15/2025 |
| Alfred Lee, MD, PhD | Faculty | Nothing to disclose - 08/14/2025 |
| Jacquelyn Powers, MD | Faculty | Nothing to disclose - 07/01/2025 |

**Notice:**

As a recognized provider by the Joint Accreditation for Interprofessional Continuing Education, we share and transmit your CE/MOC completion data with the ACCME, licensing board(s), and participating certifying boards.

**REQUIREMENTS FOR SUCCESSFUL ACTIVITY COMPLETION:**

To claim CE credits or contact hours for this activity, the participant must:

* **Have a profile in Professional Education Portal (PEP):**
1. Create an account and complete profile in (PEP).
2. Pair your email address to PEP (must use email address used to create PEP account). This is a **one-time** step in order to log your attendance using the text messaging feature in the future. Pairing your phone to the system is done by sending a **text** of your **email address** to **1-844-912-1333.**
* ​**Register** for and attend all sessions of this activity.
* ​**Record Attendance:** During the activity, the learner will TEXT the code: to **1-844-912-1333.** Learners have up to 24 hours after the activity has ended to text this code in order to record attendance.
* **​Evaluation:** Complete the participant evaluation in PEP within 30-days.
* **Claim Credit:** Claim your CE credits. Learners should claim only the credit commensurate with the extent of their participation in the activity.

**REQUIREMENTS TO EARN MOC POINTS (Physicians Only):**

* Complete the above requirements for successful activity completion.
* Click the MOC Test button.
* Complete your profile information (Specialty Board Diplomate ID and Date of Birth MM/DD) .
* Complete the MOC test. A passing score of 70% or higher is required. Unlimited attempts are allowed.

**Commercial Support:**

No commercial support has been received for this activity.